In search of biomarkers for the non-clinical recognition of AD stages, a method was suggested to distinguish cognitively healthy individuals with normal (CH-NAT) from pathological Aβ42/tau (CH-PAT) and AD. The gene discussed is MAPT; the disease is Alzheimer disease.